Patent intelligence · US
US 6635672
Agent for lowering prolactin
Agent for lowering prolactin
Patent details — US 6635672
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 21, 2003
- Expiration
- Oct 16, 2023
- Applicant
- Bionorica AG
- Claims
- 12
- CPC classes
- A61K, A61K31/045, A61K31/22, A61K31/341
Quick answer
US 6635672 (Agent for lowering prolactin) is held by Bionorica AG. Status: expired. Granted Oct 21, 2003. Expires Oct 16, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bionorica AG
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/045, A61K31/22, A61K31/341, A61P, A61P15/00
More from Bionorica AG
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 6635672?
US 6635672 (Agent for lowering prolactin) is held by Bionorica AG. Status: expired. Granted Oct 21, 2003. Expires Oct 16, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6635672?
Bionorica AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 6635672 expire?
Our index shows an expiration date of Oct 16, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.